DoctorMonique Breslin

Senior Research Fellow - Biostatistics

Menzies Institute for Medical Research

  • Senior Research Fellow - Biostatistics
    Menzies Institute for Medical Research

FUNDED PROJECTS

  • GRANT
    The Neurotoxicity Landscape: Mapping Environmental Risk Factors for Parkinson's and MND Prevalence in Australia
    1 Jul 2026 - 30 Jul 2027
    People funded by this grant:
    • de Graaff B,
    • Alty J,
    • Callisaya M,
    • Blizzard C,
    • Breslin M
    Project Total: $110,017; Approximately 90% of Parkinsons and Motor Neurone Disease (MND) cases are due to a combination of environmental and genetic factors. Environmental risk factors that have been linked to increased risk include agricultural pesticides, heavy metals (e.g. manganese) and air traffic-related pollution. Many of these toxins have been shown to induce neurodegeneration through multiple mechanisms. In response, numerous countries have banned these chemicals, however Australia has been slow to follow. For example, paraquat has been banned in 78 countries, yet the Australian regulator has been reviewing a proposed ban for more than 27 years. The aims of this project will be to generate epidemiological data to identify associations between exposure to a broad range of environmental risk factors and Parkinsons and MND. Firstly, we will geographically map Parkinsons and MND cases across Australia. We will then map environmental risk factor variables including land use (e.g. types of agriculture, mining) and air pollution, along with sociodemographic variables (alcohol and tobacco use, chronic health conditions, psychological distress, overweight and obesity). Regression models will assess associations between risk factors and prevalence of Parkinsons and MND. Importantly, we will build an online interactive map to allow users to visualise clusters of Parkinsons, MND, or both, to identify if these are associated with each of the exposures. We will use the National Health Data Hub, a longitudinal dataset that contains health data for almost all Australians (excl WA and the NT). This will be the first research of its kind globally, to bring together multiple neurodegenerative conditions and to identify associations between prevalence of these and a broad range of environmental risk factors. The findings will be critical for informing public health policy, particularly concerning the regulation of persistent environmental toxins. Funded by: Perpetual Trustees - IMPACT Philanthropy Application Program ($110,017); University of Tasmania.
  • GRANT
    Evaluating respondent burden for the EQ-HWB and EQ-HWB-S in prostate cancer
    1 Aug 2025 - 31 Jul 2027
    People funded by this grant:
    • Roydhouse J,
    • Finch A,
    • FitzGerald L,
    • Breslin M,
    • Norman R
    Project Total: $133,779; This study aims to examine respondent burden in prostate cancer. Funded by: EuroQol Foundation - Grant ($114,355); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Time to deterioration
    1 Oct 2024 - 1 Jan 2025
    People funded by this grant:
    • Roydhouse J,
    • Wills K,
    • Breslin M,
    • Otahal P,
    • Chappell K
    Project Total: $78,046; Time-to-deterioration (TTD) analyses have been used frequently for patient-reported outcome (PRO) endpoints in cancer trials, however both methodological and conceptual concerns have been raised about the use of TTD analyses. Specifically, there are concerns relating to 1) the definition of the PRO event, 2) the handling of competing risks such as death and progression. The proposed analyses aim to consider both issues and provide an evidence-based update to guide statisticians and triallists interested in using TTD for PRO data in cancer trials. The analyses will also be conducted using the estimand framework, which has been adopted or is in the process of adoption by regulatory agencies globally. This will position the analyses within ongoing developments. Funded by: Gilead Sciences ($78,046); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Developing Guidelines for COA Analytics
    16 Oct 2023 - 31 Dec 2024
    People funded by this grant:
    • Roydhouse J,
    • Breslin M
    Project Total: $16,736; The purpose of this project is to assist with the development of guidelines for clinical outcomes assessment (COA), including patient-reported outcomes (PROs). Funded by: Gilead Sciences ($16,736); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Project title: Comparison of Cardiovascular Disease Prevention Guidelines between UK, US and Australia.
    1 Apr 2017 - 1 Apr 2019
    People funded by this grant:
    • Sharman J,
    • McManus R,
    • Breslin M
    Project Total: $550; We will apply absolute CVD guidelines to national public health survey data for each country to assess proportional differences in people receiving treatment based on country guideline and population. Funded by: University of Oxford ($550); University of Tasmania.